The distributor, Medcomp Inc., won the nod from Health Canada for the Celerity device, designed to be used along with AngioDynamics’ BioFlo technology, according to a press release.
The Celerity uses ECG, rather than chest X-ray and fluoroscopy to confirm the location of a PICC in adult patients, according to the release. Distribution in Canada is slated to begin next month, AngioDynamics said.
"The ability to offer an integrated tip location system puts us in a very strong competitive position," Chuck Greiner, senior vice president of AngioDynamics’ global vascular access franchise, said in prepared remarks. "We believe the combination of the Celerity system with our market-leading, thrombus-resistant BioFlo technology may provide unparalleled clinical and economic advantages, and has the potential to become the gold standard in the PICC market."